Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 6 studies | 26% ± 8% | |
microglial cell | 5 studies | 22% ± 5% | |
macrophage | 5 studies | 23% ± 3% | |
epithelial cell | 4 studies | 24% ± 6% | |
type II pneumocyte | 4 studies | 22% ± 7% | |
astrocyte | 4 studies | 28% ± 6% | |
oligodendrocyte | 4 studies | 24% ± 4% | |
myeloid cell | 3 studies | 23% ± 10% | |
GABAergic neuron | 3 studies | 43% ± 5% | |
glutamatergic neuron | 3 studies | 55% ± 6% | |
oligodendrocyte precursor cell | 3 studies | 25% ± 5% | |
monocyte | 3 studies | 20% ± 4% | |
endothelial cell of lymphatic vessel | 3 studies | 16% ± 1% | |
fibroblast | 3 studies | 18% ± 1% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 5 studies | 36% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2178.75 | 1445 / 1445 | 100% | 13.73 | 183 / 183 |
lung | 100% | 2587.71 | 577 / 578 | 100% | 14.63 | 1153 / 1155 |
prostate | 100% | 2513.80 | 245 / 245 | 100% | 19.18 | 500 / 502 |
breast | 100% | 2607.20 | 459 / 459 | 100% | 18.96 | 1113 / 1118 |
intestine | 100% | 2578.71 | 966 / 966 | 99% | 12.64 | 524 / 527 |
bladder | 100% | 2721.05 | 21 / 21 | 99% | 12.59 | 501 / 504 |
stomach | 100% | 1957.47 | 359 / 359 | 99% | 12.72 | 284 / 286 |
thymus | 100% | 2411.36 | 653 / 653 | 99% | 15.90 | 600 / 605 |
ovary | 100% | 2263.94 | 180 / 180 | 99% | 9.51 | 425 / 430 |
brain | 99% | 1498.41 | 2613 / 2642 | 100% | 15.05 | 704 / 705 |
uterus | 100% | 2610.21 | 170 / 170 | 98% | 12.50 | 452 / 459 |
kidney | 100% | 1559.27 | 89 / 89 | 98% | 14.88 | 887 / 901 |
pancreas | 99% | 1140.78 | 324 / 328 | 99% | 14.22 | 176 / 178 |
adrenal gland | 100% | 2293.18 | 258 / 258 | 97% | 12.42 | 224 / 230 |
liver | 100% | 1351.47 | 226 / 226 | 96% | 9.93 | 391 / 406 |
skin | 100% | 2507.87 | 1809 / 1809 | 96% | 13.41 | 454 / 472 |
adipose | 100% | 2594.44 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2591.64 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 13.15 | 29 / 29 |
muscle | 100% | 2351.51 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3030.95 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 12.77 | 45 / 45 |
heart | 98% | 1901.83 | 848 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 97% | 2673.70 | 899 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 85% | 7.40 | 68 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0002250 | Biological process | adaptive immune response |
GO_0031146 | Biological process | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process |
GO_0050870 | Biological process | positive regulation of T cell activation |
GO_0070936 | Biological process | protein K48-linked ubiquitination |
GO_0010976 | Biological process | positive regulation of neuron projection development |
GO_0002842 | Biological process | positive regulation of T cell mediated immune response to tumor cell |
GO_0019005 | Cellular component | SCF ubiquitin ligase complex |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_1990756 | Molecular function | ubiquitin-like ligase-substrate adaptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | FBXO38 |
Protein name | F-box only protein 38 FBXO38 protein |
Synonyms | SP329 |
Description | FUNCTION: Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of PDCD1/PD-1, thereby regulating T-cells-mediated immunity . Required for anti-tumor activity of T-cells by promoting the degradation of PDCD1/PD-1; the PDCD1-mediated inhibitory pathway being exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival . May indirectly stimulate the activity of transcription factor KLF7, a regulator of neuronal differentiation, without promoting KLF7 ubiquitination (By similarity). . |
Accessions | ENST00000296701.10 [Q6PIJ6-3] Q6AZE0 ENST00000340253.10 [Q6PIJ6-1] Q6PIJ6 ENST00000513826.1 [Q6PIJ6-3] A0PJ52 ENST00000394370.7 [Q6PIJ6-2] |